Free Trial

Calliditas Therapeutics AB (publ) (CALT) Competitors

$39.09
+0.04 (+0.10%)
(As of 06/20/2024 ET)

CALT vs. ICPT, TVTX, ENTA, OMER, NGM, ALPN, ALKS, RNA, AXSM, and CRNX

Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Intercept Pharmaceuticals (ICPT), Travere Therapeutics (TVTX), Enanta Pharmaceuticals (ENTA), Omeros (OMER), NGM Biopharmaceuticals (NGM), Alpine Immune Sciences (ALPN), Alkermes (ALKS), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector.

Calliditas Therapeutics AB (publ) vs.

Intercept Pharmaceuticals (NASDAQ:ICPT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.

Intercept Pharmaceuticals received 1039 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 72.17% of users gave Intercept Pharmaceuticals an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.

CompanyUnderperformOutperform
Intercept PharmaceuticalsOutperform Votes
1066
72.17%
Underperform Votes
411
27.83%
Calliditas Therapeutics AB (publ)Outperform Votes
27
55.10%
Underperform Votes
22
44.90%

Intercept Pharmaceuticals has a net margin of -19.39% compared to Intercept Pharmaceuticals' net margin of -40.19%. Calliditas Therapeutics AB (publ)'s return on equity of -77.48% beat Intercept Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Intercept Pharmaceuticals-19.39% -77.48% -11.99%
Calliditas Therapeutics AB (publ) -40.19%-160.87%-30.64%

Intercept Pharmaceuticals currently has a consensus target price of $19.00, suggesting a potential upside of 0.00%. Calliditas Therapeutics AB (publ) has a consensus target price of $35.00, suggesting a potential downside of 10.46%. Given Calliditas Therapeutics AB (publ)'s higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intercept Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Calliditas Therapeutics AB (publ)
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 6.2% of Intercept Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Calliditas Therapeutics AB (publ) had 4 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 4 mentions for Calliditas Therapeutics AB (publ) and 0 mentions for Intercept Pharmaceuticals. Intercept Pharmaceuticals' average media sentiment score of 0.73 beat Calliditas Therapeutics AB (publ)'s score of 0.30 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.

Company Overall Sentiment
Intercept Pharmaceuticals Neutral
Calliditas Therapeutics AB (publ) Positive

Intercept Pharmaceuticals has higher revenue and earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intercept Pharmaceuticals$285.71M2.78$221.82M-$1.48-12.84
Calliditas Therapeutics AB (publ)$113.78M10.23-$43.96M-$1.85-21.13

Intercept Pharmaceuticals has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.

Summary

Intercept Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALT vs. The Competition

MetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.16B$6.98B$5.17B$8.42B
Dividend YieldN/A2.77%2.76%4.09%
P/E Ratio-21.1321.70160.4917.93
Price / Sales10.23224.212,159.6866.73
Price / CashN/A30.2133.6630.85
Price / Book36.885.554.744.17
Net Income-$43.96M$146.98M$110.24M$215.97M
7 Day Performance0.83%-3.20%-2.56%-1.24%
1 Month Performance81.81%-6.51%-4.98%-4.18%
1 Year Performance117.41%-9.91%-3.95%0.17%

Calliditas Therapeutics AB (publ) Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICPT
Intercept Pharmaceuticals
0.211 of 5 stars
$19.00
flat
$19.00
N/A$794.77M$285.71M-12.84341
TVTX
Travere Therapeutics
0.7314 of 5 stars
$7.10
-3.1%
$15.58
+119.5%
-60.1%$540.52M$145.24M-3.38380Positive News
ENTA
Enanta Pharmaceuticals
3.6649 of 5 stars
$11.83
-2.0%
$19.00
+60.6%
-51.6%$250.56M$79.20M-1.90145
OMER
Omeros
0 of 5 stars
$4.09
+1.2%
N/A-37.1%$236.98MN/A-2.08198
NGM
NGM Biopharmaceuticals
3.0355 of 5 stars
$1.54
-1.3%
$2.53
+64.0%
-53.5%$128.53M$4.42M-0.90138
ALPN
Alpine Immune Sciences
0.3063 of 5 stars
$64.97
flat
$52.33
-19.5%
N/A$4.46B$56.52M-101.52142
ALKS
Alkermes
4.873 of 5 stars
$24.42
-2.4%
$36.50
+49.5%
-22.8%$4.13B$1.66B9.652,100Positive News
RNA
Avidity Biosciences
0.3498 of 5 stars
$38.33
-3.2%
$44.29
+15.5%
+223.9%$3.67B$9.56M-12.99253
AXSM
Axsome Therapeutics
4.4519 of 5 stars
$76.02
+0.0%
$122.08
+60.6%
-12.7%$3.61B$270.60M-11.92545Positive News
CRNX
Crinetics Pharmaceuticals
4.0487 of 5 stars
$44.29
-0.9%
$62.50
+41.1%
+121.3%$3.49B$4.01M-11.72290Positive News

Related Companies and Tools

This page (NASDAQ:CALT) was last updated on 6/21/2024 by MarketBeat.com Staff

From Our Partners